357 related articles for article (PubMed ID: 36513244)
21. Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.
van 't Erve I; Medina JE; Leal A; Papp E; Phallen J; Adleff V; Chiao EJ; Arun AS; Bolhuis K; Simmons JK; Karandikar A; Valkenburg KC; Sausen M; Angiuoli SV; Scharpf RB; Punt CJA; Meijer GA; Velculescu VE; Fijneman RJA
Clin Cancer Res; 2023 Mar; 29(5):899-909. PubMed ID: 36534496
[TBL] [Abstract][Full Text] [Related]
22. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.
Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ
J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598
[TBL] [Abstract][Full Text] [Related]
23. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
Mansukhani S; Barber LJ; Kleftogiannis D; Moorcraft SY; Davidson M; Woolston A; Proszek PZ; Griffiths B; Fenwick K; Herman B; Matthews N; O'Leary B; Hulkki S; Gonzalez De Castro D; Patel A; Wotherspoon A; Okachi A; Rana I; Begum R; Davies MN; Powles T; von Loga K; Hubank M; Turner N; Watkins D; Chau I; Cunningham D; Lise S; Starling N; Gerlinger M
Clin Chem; 2018 Nov; 64(11):1626-1635. PubMed ID: 30150316
[TBL] [Abstract][Full Text] [Related]
24. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
Osumi H; Shinozaki E; Takeda Y; Wakatsuki T; Ichimura T; Saiura A; Yamaguchi K; Takahashi S; Noda T; Zembutsu H
Cancer Med; 2019 Jan; 8(1):408-417. PubMed ID: 30575318
[TBL] [Abstract][Full Text] [Related]
25. Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
Salvianti F; Gelmini S; Mancini I; Pazzagli M; Pillozzi S; Giommoni E; Brugia M; Di Costanzo F; Galardi F; De Luca F; Castiglione F; Messerini L; Pinzani P; Antonuzzo L
Br J Cancer; 2021 Jul; 125(1):94-100. PubMed ID: 33953347
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS/NRAS/BRAF genotyping for metastatic colorectal cancer.
Huang F; Yang Y; Chen X; Jiang H; Wang H; Shen M; Yu Y; Liu T; Pan B; Wang B; Guo W
Clin Biochem; 2021 Jun; 92():46-53. PubMed ID: 33737000
[TBL] [Abstract][Full Text] [Related]
27. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.
Serrano C; Vivancos A; López-Pousa A; Matito J; Mancuso FM; Valverde C; Quiroga S; Landolfi S; Castro S; Dopazo C; Sebio A; Virgili AC; Menso MM; Martín-Broto J; Sansó M; García-Valverde A; Rosell J; Fletcher JA; George S; Carles J; Arribas J
BMC Cancer; 2020 Feb; 20(1):99. PubMed ID: 32024476
[TBL] [Abstract][Full Text] [Related]
28. Analysis of colorectal cancer-related mutations by liquid biopsy: Utility of circulating cell-free DNA and circulating tumor cells.
Takeda K; Yamada T; Takahashi G; Iwai T; Ueda K; Kuriyama S; Koizumi M; Matsuda A; Shinji S; Ohta R; Yokoyama Y; Hotta M; Hara K; Yoshida H
Cancer Sci; 2019 Nov; 110(11):3497-3509. PubMed ID: 31465598
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer.
Yu H; Han L; Yuan J; Sun Y
Cancer Biomark; 2020; 27(1):29-37. PubMed ID: 31658042
[TBL] [Abstract][Full Text] [Related]
30. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.
Zhao J; Reuther J; Scozzaro K; Hawley M; Metzger E; Emery M; Chen I; Barbosa M; Johnson L; O'Connor A; Washburn M; Hartje L; Reckase E; Johnson V; Zhang Y; Westheimer E; O'Callaghan W; Malani N; Chesh A; Moreau M; Daber R
Mol Diagn Ther; 2023 Nov; 27(6):753-768. PubMed ID: 37632661
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis.
Xie W; Xie L; Song X
Cancer Med; 2019 Mar; 8(3):1218-1231. PubMed ID: 30791218
[TBL] [Abstract][Full Text] [Related]
32. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
33. Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients.
Park G; Park JK; Son DS; Shin SH; Kim YJ; Jeon HJ; Lee J; Park WY; Lee KH; Park D
Sci Rep; 2018 Aug; 8(1):11631. PubMed ID: 30072705
[TBL] [Abstract][Full Text] [Related]
34. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.
Moati E; Blons H; Taly V; Garlan F; Wang-Renault SF; Pietrasz D; Didelot A; Garrigou S; Saint A; Pernot S; Taieb J; Laurent-Puig P; Zaanan A
Int J Cancer; 2020 Aug; 147(4):1185-1189. PubMed ID: 31472013
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of a Liquid Biopsy Protocol using Ultra-Deep Massive Parallel Sequencing for Detecting and Quantifying Circulation Tumor DNA in Colorectal Cancer Patients.
Nguyen HT; Tran DH; Ngo QD; Pham HT; Tran TT; Tran VU; Pham TN; Le TK; Le NT; Nguyen NM; Vo BT; Nguyen LT; Nguyen TV; Bui QTN; Nguyen HN; Luong BA; Le LGH; Do DM; Do TT; Hoang AV; Dinh KT; Phan MD; Tran LS; Giang H; Nguyen HN
Cancer Invest; 2020 Feb; 38(2):85-93. PubMed ID: 31939681
[TBL] [Abstract][Full Text] [Related]
36. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
37. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
[TBL] [Abstract][Full Text] [Related]
38. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
[TBL] [Abstract][Full Text] [Related]
39. Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy.
Hendricks A; Rosenstiel P; Hinz S; Burmeister G; Röcken C; Boersch K; Schafmayer C; Becker T; Franke A; Forster M
BMC Med Genet; 2020 Jan; 21(1):3. PubMed ID: 31900123
[TBL] [Abstract][Full Text] [Related]
40. Detection of mutational patterns in cell-free DNA of colorectal cancer by custom amplicon sequencing.
Herrmann S; Zhan T; Betge J; Rauscher B; Belle S; Gutting T; Schulte N; Jesenofsky R; Härtel N; Gaiser T; Hofheinz RD; Ebert MP; Boutros M
Mol Oncol; 2019 Aug; 13(8):1669-1683. PubMed ID: 31254442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]